TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12166512

Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: No treatment (untreated patients)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 51
Study: 9489580

Group type: EXPERIMENTAL
Intervention: Psychological outreach programmes
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapies
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Group interventions
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Interventions with more female participants
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Interventions offering more sessions
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Overall dropout rate
Number of subjects: 14
Study: 8194505

Group type: EXPERIMENTAL
Intervention: Zinc with 600 mg elemental calcium as calcium carbonate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Zinc with 600 mg elemental calcium as calcium citrate
Number of subjects: 9

Group type: COMPARATOR
Intervention: Zinc alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 9
Study: 3651528

Group type: EXPERIMENTAL
Intervention: RS 86 (oral, long-acting muscarinic agonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31030965

Group type: EXPERIMENTAL
Intervention: Silver-coated silicone Foley catheters
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal silicone Foley catheters
Number of subjects: 54
Study: 27900813

Group type: EXPERIMENTAL
Intervention: 2% sevoflurane at 1 l·min‐1 fresh gas flow [O2 : N2 O = 50 : 50]
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fresh gas flow reduced to 0.5 l·min‐1 [O2 : N2 O = 50 : 50] (control group)
Number of subjects: 50
Study: 25840693

Group type: EXPERIMENTAL
Intervention: Ipilimumab (10 mg/kg, intravenous infusions every 3 weeks for four doses, then every 3 months for up to 3 years)
Number of subjects: 951

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 951
Study: 23838728

Group type: EXPERIMENTAL
Intervention: COMPASS intervention
Number of subjects: 47
Study: 21667450

Group type: EXPERIMENTAL
Intervention: Long-term psychoanalytic treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 28
Study: 19491826

Group type: EXPERIMENTAL
Intervention: Rifaximin for 7 days
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 16776756

Group type: EXPERIMENTAL
Intervention: ProFile .04 taper rotary instruments
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anatomic Endodontic Technology (AET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual instrumentation with Hedström files
Number of subjects: 60
Study: 12766064

Group type: EXPERIMENTAL
Intervention: CIGTS VF score
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: CIGTS MD
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: CIGTS VF score variability
Number of subjects: 607
Study: 11194979

Group type: EXPERIMENTAL
Intervention: 3 micrograms.kg‐1 fentanyl
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1 microgram.kg‐1 remifentanil
Number of subjects: 30
Study: 9375949

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg IV divided into 3 injections, then 200 mg orally daily for 3 months)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (for patients with signs of CHF)
Number of subjects: 131
Study: 1492579

Group type: EXPERIMENTAL
Intervention: Progesterone solution in almond oil, 2 mg/0.1 ml (total dose approximately 11 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Progesterone solution in dimethicone, 5 mg/0.1 ml (total dose approximately 28 mg)
Number of subjects: 20
Study: 2981088

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31403817

Group type: EXPERIMENTAL
Intervention: Culturally adapted motivational interviewing (CAMI)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Standard motivational interviewing (MI)
Number of subjects: 296
Study: 30006308

Group type: EXPERIMENTAL
Intervention: Test of Diabetes Knowledge for Teachers (TDKT)
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Questions about symptoms and hypoglycaemia treatment
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Teaching experience and subject taught
Number of subjects: 756
Study: 26142345

Group type: EXPERIMENTAL
Intervention: Combination nicotine replacement therapy (cNRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 23778343

Group type: EXPERIMENTAL
Intervention: Saint John's wort (300 mg daily for three months)
Number of subjects: 21
Study: 21492066

Group type: EXPERIMENTAL
Intervention: Early preventive rehabilitation
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 190
Study: 18791717

Group type: EXPERIMENTAL
Intervention: Tocosol Paclitaxel (175 mg/m², 15 min infusion)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Taxol (175 mg/m², 3 h infusion)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tocosol Paclitaxel
Number of subjects: 35

Group type: COMPARATOR
Intervention: Taxol
Number of subjects: 35
Study: 17348991

Group type: COMPARATOR
Intervention: Topical 2% N-acetyl glucosamine (NAG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical combination of 2% N-acetyl glucosamine (NAG) with 4% niacinamide
Number of subjects: 0
Study: 15365622

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 11518072

Group type: COMPARATOR
Intervention: Jarsin 300 (9 tablets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LI 160
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperforin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypericin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ketanserin (5‐HT2 receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: WAY‐100635 (5‐HT1A antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol (DA antagonist)
Number of subjects: 0
Study: 7841729

Group type: EXPERIMENTAL
Intervention: Inhalation of racemic adrenaline
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (no racemic adrenaline)
Number of subjects: 54
Study: 2905636

Group type: EXPERIMENTAL
Intervention: 10 mg ketorolac tromethamine
Number of subjects: 96

Group type: COMPARATOR
Intervention: 400 mg glafenine
Number of subjects: 96
Study: 31377215

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham-mindfulness meditation
Number of subjects: 62
Study: 29570376

Group type: EXPERIMENTAL
Intervention: Protocol A (two acquisitions: 35-second delayed CT for chest and 70-second delayed abdominal acquisition)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Protocol B (single 60-second delayed acquisition covering chest and abdomen)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Protocol A
Number of subjects: 77

Group type: COMPARATOR
Intervention: Protocol B
Number of subjects: 77
Study: 28567698

Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: olanzapine
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: quetiapine
Number of subjects: 493

Group type: COMPARATOR
Intervention: Overall
Number of subjects: 493
Study: 26416458

Group type: EXPERIMENTAL
Intervention: KRAS mutated patients
Number of subjects: 247

Group type: COMPARATOR
Intervention: KRAS wild-type patients
Number of subjects: 247
Study: 23840296

Group type: EXPERIMENTAL
Intervention: Sodium Ferulate (SF) pretreatment for 14 days with bupropion (150 mg)
Number of subjects: 33
Study: 21205368

Group type: EXPERIMENTAL
Intervention: Adenoidectomy plus tympanostomy tube insertion (n = 25)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Adenoidectomy plus myringotomy (n = 27)
Number of subjects: 52
Study: 18050282

Group type: EXPERIMENTAL
Intervention: T-Scan+ women (identified by Electrical Impedance Scanning)
Number of subjects: 2141
Study: 16476115

Group type: EXPERIMENTAL
Intervention: Complex PIL (Patient Information Leaflet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simple PIL incorporating pictograms
Number of subjects: 0

Group type: COMPARATOR
Intervention: No PIL (Control group)
Number of subjects: 0
Study: 14643034

Group type: EXPERIMENTAL
Intervention: 200 microg oral misoprostol
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 10923073

Group type: EXPERIMENTAL
Intervention: Erythrocyte anion exchange measurement in patients with AD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythrocyte anion exchange measurement in age-matched controls
Number of subjects: 0
Study: 9024268

Group type: EXPERIMENTAL
Intervention: 2 mg 17-beta-estradiol orally for 3 months (with 1 mg norethisterone acetate added for 10 days during the last 16 days for endometrial protection)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 8024294

Group type: EXPERIMENTAL
Intervention: Salbutamol (800 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3305221

Group type: EXPERIMENTAL
Intervention: Myelosuppressive postinduction treatment
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Monthly maintenance chemotherapy
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Intensive two-course preremission therapy
Number of subjects: 877
Study: 31518715

Group type: EXPERIMENTAL
Intervention: Absence of iodine staining at baseline chromoendoscopy
Number of subjects: 1468

Group type: EXPERIMENTAL
Intervention: Model based on patient age, body mass index, pathology findings, and baseline iodine staining
Number of subjects: 1468
Study: 30595271

Group type: EXPERIMENTAL
Intervention: RADPAD
Number of subjects: 65

Group type: COMPARATOR
Intervention: No RADPAD
Number of subjects: 65
Study: 26699899

Group type: EXPERIMENTAL
Intervention: Atorvastatin (initial dose of 40 mg at admission followed by 10 mg/day for 30 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no statin treatment)
Number of subjects: 0
Study: 26121897

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 23563500

Group type: EXPERIMENTAL
Intervention: Rehabilitation initiated 6 weeks after LSF
Number of subjects: 82

Group type: COMPARATOR
Intervention: Rehabilitation initiated 12 weeks after LSF
Number of subjects: 82
Study: 21916603

Group type: EXPERIMENTAL
Intervention: Low vitamin D status (serum 25-hydroxyvitamin D < 32 ng/mL)
Number of subjects: 884

Group type: EXPERIMENTAL
Intervention: Low vitamin D levels
Number of subjects: 884
Study: 18254812

Group type: EXPERIMENTAL
Intervention: BoNTA (Ipsen)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BoNTA (Allergan)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study: 16629780

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 0
Study: 14637136

Group type: EXPERIMENTAL
Intervention: Presence of GSTT1 and GSTM1 functional alleles
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: One functional allele (either GSTT1 or GSTM1)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (healthy subjects matched for age and sex, 27 subjects)
Number of subjects: 41
Study: 10757852

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program for 30 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study: 8666630

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patellar retention
Number of subjects: 40
Study: 8417634

Group type: EXPERIMENTAL
Intervention: Glipizide 10 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Glipizide 20 mg
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Glipizide 40 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 3777463

Group type: EXPERIMENTAL
Intervention: Local anesthetic solution with hyaluronidase (75 international units diluted in 5 ml of local anesthetic mixture)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Local anesthetic solution without hyaluronidase
Number of subjects: 100
Study: 29558953

Group type: EXPERIMENTAL
Intervention: Gum Arabic (30 g daily for 3 months)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (5 g daily for 3 months)
Number of subjects: 91
Study: 29911358

Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac with 0.5% loteprednol
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.5% loteprednol alone
Number of subjects: 80
Study: 25066102

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT) with booster program
Number of subjects: 101

Group type: COMPARATOR
Intervention: Internet-based cognitive behavior therapy (ICBT) without booster program
Number of subjects: 101
Study: 22320186

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (PostC) following percutaneous coronary intervention (PCI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (PostC)
Number of subjects: 20
Study: 20084409

Group type: EXPERIMENTAL
Intervention: Caudal blockade with 0.5% bupivacaine [10 ml x height (m)]
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 51
Study: 19453397

Group type: EXPERIMENTAL
Intervention: FluBlok, a recombinant trivalent hemagglutinin vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional egg-based trivalent inactivated influenza vaccine (TIV)
Number of subjects: 0
Study: 15935019

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 200 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 400 mg
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 12856480

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 10789188

Group type: EXPERIMENTAL
Intervention: Bioelectric impedance measurements with 2-liters dialysate volume
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bioelectric impedance measurements
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (10 healthy volunteers)
Number of subjects: 33
Study: 8676421

Group type: EXPERIMENTAL
Intervention: VO2I > or = 150 or DO2I > or = 600 mL/min/m2 (Group 1)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional parameters (Group 2)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: VO2I/DO2I goals (Group 1)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Group 1 (after excluding those who failed VO2I/DO2I goals)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Group 2 (after excluding the patient who died of refractory shock)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: All patients maintaining mean DO2I > or = 600 during the first 24 hours
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: All patients not maintaining mean DO2I > or = 600 during the first 24 hours
Number of subjects: 58
Study: 1804599

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g once daily + Amikacin 0.5 g
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ceftazidime 2 g twice daily + Amikacin 0.5 g b.i.d.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ceftriaxone/Amikacin
Number of subjects: 50
Study: 6097173

Group type: EXPERIMENTAL
Intervention: 2.0 g of sulbactam given in a single intramuscular dose with 1.0 g of probenecid orally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5 g of intramuscular sulbactam given twice, 4 h apart
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Geometric mean MIC of sulbactam for 20 pretreatment isolates of N. gonorrhoeae
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Serum levels of sulbactam
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 20
Study: 31378647

Group type: EXPERIMENTAL
Intervention: Taste Exposure (TE)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Nutrition Education (NE)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Taste Exposure + Nutrition Education (TE+NE)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 219
Study: 29671280

Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab 200 mg
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 27008417

Group type: EXPERIMENTAL
Intervention: Rechargeable incentive cards (RICs)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Money orders (MOs)
Number of subjects: 303
Study: 25280456

Group type: EXPERIMENTAL
Intervention: 5° lateral wedging
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-wedged condition
Number of subjects: 14
Study: 22277052

Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 271

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 271
Study: 20434024

Group type: EXPERIMENTAL
Intervention: Summary-of-findings (SoF) table
Number of subjects: 110
Study: 18525042

Group type: EXPERIMENTAL
Intervention: Hypothermia therapy (32.5 degrees C for 24 hours)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Normothermia (37.0 degrees C)
Number of subjects: 225
Study: 15661600

Group type: EXPERIMENTAL
Intervention: Trauma Symptom Checklist for Children (TSCC)
Number of subjects: 120
Study: 11795752

Group type: EXPERIMENTAL
Intervention: Complete anterior discectomy (Group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Partial reamed channel discectomy (Group 2)
Number of subjects: 100
Study: 10436288

Group type: EXPERIMENTAL
Intervention: Personalized advice and assistance including self-help materials tailored for pregnancy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intensive counseling on multiple occasions
Number of subjects: 16
Study: 7677238

Group type: EXPERIMENTAL
Intervention: Cellulose fabric face mask
Number of subjects: 9

Group type: COMPARATOR
Intervention: Woolen scarf
Number of subjects: 9

Group type: COMPARATOR
Intervention: No face mask
Number of subjects: 9
Study: 2265493

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: M. leprae only
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: BCG + M. leprae
Number of subjects: 270
Study: 7085368

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (cefazolin or carbenicillin, three perioperative doses)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no prophylactic antibiotics)
Number of subjects: 118
Study: 31495389

Group type: EXPERIMENTAL
Intervention: Medical centre- and home-based cardiac rehabilitation program
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (recommendation to perform exercise at home in an uncontrolled setting)
Number of subjects: 36
Study: 28130475

Group type: EXPERIMENTAL
Intervention: Annual screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Personalized screening
Number of subjects: 0
Study: 26360974

Group type: EXPERIMENTAL
Intervention: Kinesiology Tape (KT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo tape
Number of subjects: 30
Study: 23394404

Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (Sequent please; B. Braun) followed by bare metal stent (Coroflex Blue; B. Braun)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Drug-eluting stent (Resolute Integrity; Boston Scientific)
Number of subjects: 180
Study: 21247998

Group type: EXPERIMENTAL
Intervention: ondansetron (4 μg/kg twice daily)
Number of subjects: 283

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 283
Study: 19959692

Group type: EXPERIMENTAL
Intervention: Expired carbon monoxide (CO)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Plasma cotinine (COT)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: CYP2A6 activity
Number of subjects: 700
Study: 17179442

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Submotor electrical stimulation (ES)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 34
Study: 15252886

Group type: EXPERIMENTAL
Intervention: Cycloid psychosis
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Schizophrenia
Number of subjects: 77

Group type: COMPARATOR
Intervention: Controls (48 individuals)
Number of subjects: 77
Study: 11593458

Group type: EXPERIMENTAL
Intervention: Videotape preparation before hip replacement surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no videotape preparation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Videotape preparation
Number of subjects: 100
Study: 9512197

Group type: EXPERIMENTAL
Intervention: Aptamil-LCP
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard Aptamil
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 61
Study: 8063242

Group type: EXPERIMENTAL
Intervention: Cold knife conization
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Laser conization
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: LEEP
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 110
Study: 2657467

Group type: EXPERIMENTAL
Intervention: Pyridostigmine 60 mg orally
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 125133

Group type: EXPERIMENTAL
Intervention: Methandienone 10 mg/day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Methandienone 25 mg/day
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31912305

Group type: EXPERIMENTAL
Intervention: Thermal hydrokinesiotherapy
Number of subjects: 11